Through a collective analysis encompassing molecular docking insights, immunoprecipitation data, and RNA silencing experiments, it became evident that MSLN, a recognized tumor differentiation antigen, played a significant role in mediating the anti-tumor effects of PSCA (Figure 8C). The gene discussed is MSLN; the disease is neoplasm.